Pheochromocytoma: State-of-the-art and future prospects

Endocrine Reviews

Volumn 24, Issue 4, 2003, Pages 539-553

  Bravo, Emmanuel L ^a   Tagle, Rodrigo ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; METADRENALIN; NEUROHORMONE;

ADRENERGIC SYSTEM; CHEMICAL ANALYSIS; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; FAMILIAL DISEASE; GENE MUTATION; GENETIC DISORDER; HEMODYNAMICS; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION;

ADRENAL GLAND NEOPLASMS; AGED; CATECHOLAMINES; CHROMOGRANIN A; CHROMOGRANINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; METANEPHRINE; PHEOCHROMOCYTOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0042854912     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2002-0013     Document Type: Review

References (113)

1. Crout JR, Pisano JJ, Sjoerdsma A 1961 Urinary excretion of catecholamines and their metabolites in pheochromocytoma. Am Heart J 61:375-381
2. Crout JR, Sjoerdsma A 1964 Turnover and metabolism of catecholamine in patients with pheochromocytoma. J Clin Invest 43: 94-102
3. Peuler JD, Johnson GA 1977 Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21:625-636
4. Goldstein DS, Feuerstein G, Izzo Jr JL, Kopin IJ, Keiser HR 1981 Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 28:467-475
5. Stewart BH, Bravo EL, Haaga J, Meaney TF, Tarazi R 1978 Localization of pheochromocytoma by computed tomography. N Engl J Med 299:460-461
6. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Beierwaltes WH, Thompson NW 1981 Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12-17
7. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT 1983 Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58:802-804
8. Stenstrom G, Svardsudd K 1986 Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry data. Acta Med Scand 220:225-232
9. Smythe GA, Edwards G, Graham P, Lazarus L 1992 Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clin Chem 38:486-492
10. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM 2000 Pheochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 30:648-652
11. Kudva YC, Young Jr WF, Thompson GB, Grant CS, van Heerden JA 1999 Adrenal incidentaloma: an important component of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. Endocrinologist 9:77-80
12. Bravo EL, Tarazi RC, Gifford Jr RW, Stewart BH 1979 Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301:682-686
13. Bravo EL 2002 Pheochromocytoma: an approach to antihypertensive therapy. Ann NY Acad Sci 970:1-10
14. Page LB, Raker JW, Berberich FR 1969 Pheochromocytoma with predominant epinephrine secretion. Am J Med 47:648-652
15. Plouin PF, Degoulet P, Tugaye A, Ducrocq MB, Menard J 1981 [Screening for phaeochromocytoma: in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)]. Nouv Presse Med 10:869-872 (French)
16. Bravo EL 1991 Pheochromocytoma: new concepts and future trends. Kidney Int 40:544-556
17. Sutton MG, Sheps SG, Lie JT 1981 Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 56:354-360
18. Hartley L, Perry-Keene D 1985 Phaeochromocytoma in Queensland-1970-83. Aust N Z J Surg 55:471-475
19. Krane NK 1986 Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature. Arch Intern Med 146:54-57
20. Bravo EL, Fouad-Tarazi FM, Rossi G, Imamura M, Lin WW, Madkour MA, Cressman MD, Saragoca M 1990 A reevaluation of the hemodynamics of pheochromocytoma. Hypertension 15:I128-I131
21. Bravo EL, Tarazi RC, Fouad FM, Textor SC, Gifford Jr RW, Vidt DG 1982 Blood pressure regulation in pheochromocytoma. Hypertension 4:193-199
22. Johnson MD, Smith PG, Mills E, Schanberg SM 1983 Paradoxical elevation of sympathetic activity during catecholamine infusion in rats. J Pharmacol Exp Ther 227:254-259
23. Langer SZ, Cavero I, Massingham R 1980 Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 2:372-382
24. Tsujimoto G, Honda K, Hoffman BB, Hashimoto K 1987 Desensitization of postjunctional alpha 1- and alpha 2-adrenergic receptor-mediated vasopressor responses in rat harboring pheochromocytoma. Circ Res 61:86-98
25. Prokocimer PG, Maze M, Hoffman BB 1987 Role of the sympathetic nervous system in the maintenance of hypertension in rats harboring pheochromocytoma. J Pharmacol Exp Ther 241:870-874
26. Grassi G, Seravalle G, Tutti C, Mancia G 1999 Sympathetic nerve traffic responses to surgical removal of pheochromocytoma. Hypertension 34:461-465
27. Floras JS, Hara K 1993 Sympathoneural and hemodynamic characteristics of young subjects with mild hypertension. J Hypertens 11:647-655
28. Grassi G, Bolla G, Seravalle G, Tutti C, Lanfranchi A, Mancia G 1997 Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci 92:285-289
29. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Sasaki S, Noma K, Matsuura H, Hara K, Goto C, Oshima T, Chayama K 2002 Excess norepinephrine impairs both endothelium-dependent and -independent vasodilation in patients with pheochromocytoma. Hypertension 39(2 Pt 2):513-518
30. des Senanayake P, Denker J, Bravo EL, Graham RM 1995 Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 96:2503-2509
31. Corder R, Emson PC, Lowry PJ 1984 Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue. Biochem J 219:699-706
32. Lundberg JM, Hokfelt T, Hemsen A, Theodorsson-Norheim E, Pernow J, Hamberger B, Goldstein M 1986 Neuropeptide Y-like immunoreactivity in adrenaline cells of adrenal medulla and in tumors and plasma of pheochromocytoma patients. Regul Pept 13:169-182
33. O'Hare MMT, Schwartz TW 1989 Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors. Cancer Res 49:7010-7014
34. Lundberg JM, Tatemoto K 1982 Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand 116:393-402
35. Herzog HY, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA 1992 Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 89:5794-5798
36. Wahlestedt C, Edvinsson L, Ekblad E, Hakanson R 1985 Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 234:735-741
37. Macho PR, Perez R, Huidobro-Toro JP, Domenech RJ 1989 Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur J Pharmacol 167: 67-74
38. Hauptman JB, Modlinger RS, Ertel NH 1983 Pheochromocytoma resistant to alpha-adrenergic blockade. Arch Intern Med 143:2321-2323
39. Perel Y, Schlumberger M, Marguerite G, Alos N, Revillon Y, Sommelet D, De Lumley L, Flamant F, Dyon JF, Lutz P, Heloury H, Lemerle J 1997 Pheochromocytoma and paraganglioma in children: a report of 24 cases of the French Society of Pediatric Oncology. Pediatr Hematol Oncol 14:413-422
40. Gagel RE, Tashjian Jr AH, Cummings T, Papathanasopoulos N, Kaplan NM, Wolfe HJ, Reichlin S 1988 The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318:478-484
41. Bravo EL, Gifford Jr RW 1984 Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311:1298-1303
42. Hoff AO, Cote GJ, Gagel RF 2000 Multiple endocrine neoplasia. Annu Rev Physiol 62:377-411
43. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G 1993 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531-1538
44. Evans DB, Lee JE, Merrell RC, Hickey RC 1994 Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol Metab Clin North Am 23:167-176
45. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM 1999 von Recklinghausen's disease and pheochromocytoma. J Urol 162: 1582-1596
46. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ 1993 Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39:97-103
47. Bravo EL 1996 Adrenal medullary function. In: Moore WT, Eastman RC, eds. Diagnostic endocrinology. 2nd ed. St. Louis: Mosby-Year Book, Inc.; 299-309
48. O'Connor DT, Frigon RP 1984 Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 259: 3237-3247
49. O'Connor DT, Bernstein KN 1984 Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 311:764-770
50. Canale MP, Bravo EL 1994 Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 78:1139-1144
51. Eisenhofer G, Walther M, Keiser HR, Lenders JW, Friberg P, Pacak K 2000 Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Braz J Med Biol Res 33:1157-1169
52. Lenders JW, Keiser HHR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppeborg PN, Thien T, Eisenhofer G 1995 Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 123:101-109
53. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR 1999 Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879
54. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W, Roden M 2000 Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160:2957-2963
55. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287:1427-1434
56. Sawka AM, Singh RJ, Young Jr WF, Fractionated plasma metanephrines are highly sensitive but less specific than urinary total metanephrines and catecholamines in detection of pheochromocytoma. Program of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 285 (Abstract PI-642)
57. Feldman JM 1987 Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy. J Clin Pharmacol 27:288-292
58. Cook FJ, Chandler DW, Snyder DK 1995 Effect of buspirone on urinary catecholamine assays. N Engl J Med 332:401
59. Lawrence AM 1967 Glucagon provocative test for pheochromocytoma. Ann Intern Med 66:1091-1096
60. Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford Jr RW 1981 Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 305:623-626
61. Bravo EL 1994 Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocr Rev 15:356-368
62. Whalen RK, Althausen AF, Daniels GH 1992 Extra-adrenal pheochromocytoma. J Urol 147:1-10
63. Ross EJ, Prichard BN, Kaufman L, Robertson AI, Harries BJ 1967 Preoperative and operative management of patients with phaeochromocytoma. Br Med J 1:191-198
64. Perry LB, Gould Jr AB 1972 The anesthetic management of pheochromocytoma effect of preoperative adrenergic blocking drugs. Anesth Analg 51:36-40
65. Desmonts JM, Marty J 1984 Anaesthetic management of patients with phaeochromocytoma. Br J Anaesth 56:781-789
66. Newell KA, Prinz RA, Brooks MHH, Glisson SN, Barbato AL, Freeark RJ 1988 Plasma catecholamine changes during excision of pheochromocytoma. Surgery 104:1064-1073
67. Boutros AR, Bravo EL, Zanettin G, Straffon RA 1990 Perioperative management of 63 patients with pheochromocytoma. Cleve Clin J Med 57:613-617
68. Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC 1999 Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 161:764-767
69. Hoffman BB 2001 Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists In: Hardman JG, Lombard LE. Goodman & Gillman's the Pharmacological basis of therapeutics. Philadelphia; McGraw-Hill; 215-268
70. Serfas D, Shoback DM, Lorell BH 1983 Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade. Lancet 2:711-713
71. Takahashi S, Nakai T, Fujiwara R, Kutsumi Y, Tamai T, Miyabo S 1989 Effectiveness of long-acting nifedipine in pheochromocytoma. Jpn Heart J 30:751-757
72. Lenders JW, Sluiter HE, Thien T, Willemsen J 1985 Treatment of a phaeochromocytoma of the urinary bladder with nifedipine. Br Med J Clin Res 290:1624-1625
73. Favre L, Vallotton MB 1986 Nifedipine in pheochromocytoma. Ann Intern Med 104:125 (Letter)
74. Lehmann HU, Hochrein H, Witt E, Mies HW 1983 Hemodynamic effects of calcium antagonists. Hypertension 5:II66-II73 (Review)
75. Bravo EL 2001 Secondary hypertension: adrenal and nervous systems. In: Hollenberg NK. Atlas of heart diseases. Philadelphia: Current Medicine; 118-143
76. Proye C, Thevenin D, Cecat P, Petillot P, Carnaille B, Verin P, Racadot N 1989 Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery 106:1149-1154
77. Tokioka H, Takahashi T, Kosogabe Y, Ohta Y, Kosaka F 1988 Use of nicardipine hydrochloride to control circulatory fluctuations during resection of a phaeochromocytoma. Br J Anaesth 60:582-587
78. Sprung J, O'Hara Jr JF, Gill IS, Abdelmalak B, Sarnaik A, Bravo EL 2000 Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. Urology 55:339-343
79. Tsuchimochi S, Nakajo M, Nakabeppu Y, Tani A 1997 Metastatic pulmonary pheochromocytomas: positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging. Clin Nucl Med 22:687-690
80. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC 1986 Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 11:851-854
81. Krenning EP, Kwekkeboom DJ, Pauwels J 1995 Somatostatin receptor scintigraphy. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press; 1-50
82. Strauss LG, Conti PS 1991 The applications of PET in clinical oncology. J Nucl Med 32:623-648
83. Neumann DR, Basile KE, Bravo EL, Chen EQ, Go RT 1996 Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. J Comput Assist Tomogr 20:312-316
84. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35-41
85. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE 1992 PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33:1125-1131
86. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS 2001 6-[18F]Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38:6-8
87. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan WM 1998 Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423
88. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells Jr SA 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856
89. Neumann HP, Eng C, Mulligan LM, Glavac D, Zauner I, Ponder BA, Crossey PA, Maher ER, Brauch H 1995 Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 274: 1149-1151
90. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
91. Eng C 1996 Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335:943-951
92. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard III CW, Cornelisse CJ, Devilee P, Devlin B 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 287:848-851
93. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F, Maher ER 2001 Germline SDHD mutation in familial phaeochromocytoma Lancet 357:1181-1182
94. Nakamura K, Yamaki M, Sarada M, Nakayama S, Vibat CR, Gennis RB, Nakayashiki T, Inokuchi H, Kojima S, Kita K 1996 Two hydrophobic subunits are essential for the heme b ligation and functional assembly of complex II (succinate-ubiquinone oxidoreductase) from Escherichia coli. J Biol Chem 271:521-527
95. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
96. Aprill BS, Drake III AJ, Lasseter DH, Shakir KM 1994 Silent adrenal nodules in von Hippel-Lindau disease suggest pheochromocytoma. Ann Intern Med 120:485-487
97. Lairmore TC, Ball DW, Baylin SB, Wells Jr SA 1993 Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 217:595-601; discussion 601
98. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC 1996 Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120:1064-1070
99. Telenius-Berg M, Ponder MA, Berg B, Ponder BA, Werner S 1989 Quality of life after bilateral adrenalectomy in MEN 2. Henry Ford Hosp Med J 37:160-163
100. Albanese CT, Wiener ES 1993 Routine total bilateral adrenalectomy is not warranted in childhood familial pheochromocytoma. J Pediatr Surg 28:1248-1251
101. Remine WH, Chong GC, van Heerden JA, Sheps SG, Harrison Jr EG 1974 Current management of pheochromocytoma. Ann Surg 179:740-748
102. Nativ O, Grant CS, Sheps SG, O'Fallon JR, Farrow GM, van Heerden JA, Lieber MM 1992 The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 69:2683-2687
103. Salmenkivi K, Arola J, Voutilainen R, Ilvesmaki V, Haglund C, Kahri AI, Heikkila P, Liu J 2001 Inhibin/activin/βB-subtmit expression in pheochromocytomas favors benign diagnosis J Clin Endocrinol Metab 86:2231-2235
104. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA 1989 Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 7:1720-1725
105. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR 1988 Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109:267-273
106. 131]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35:269-276
107. Pacak K, Fojo T, Goldstein DS, Eisenhofer G, Walther MM, Linehan WM, Bachenheimer L, Abraham J, Wood BJ 2001 Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 93:648-649
108. Bravo EL, Gifford Jr RW, Manger WM 1993 Adrenal medullary tumors: pheochromocytoma. In: Mazzaferri EL, Samann NA, eds. Endocrine tumors. Boston: Blackwell Scientific Publishers; 1426-1448
109. Bravo EL 2002 Pheochromocytoma. J Cardiol Rev 10:44-50
110. Sawka AM, Jaeschke R, Singh RJ, Young Jr WF 2003 A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553-558
111. Eisenhofer G 2003 Editorial: biochemical diagnosis of pheochromocytoma - is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 88:550-552
112. Hes FJ, Hoppener JW, Lips CJ 2003 Clinical review 155: pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 88:969-974
113. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ, Robinson BG 2003 Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22:1358-1364